Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB/ SE0000872095 /
SOBI
5/28/2024 5:29:58 PM
|
Chg.
-
|
Volume |
Bid5:29:58 PM |
Ask5:29:58 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
275.80SEK
|
-
|
313,075 Turnover: 81.38 mill. |
275.20Bid Size: 1,392 |
275.60Ask Size: 224 |
97.73 bill.SEK |
- |
36.92 |
Business description
Swedish Orphan Biovitrum AB is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
Management board & Supervisory board
CEO |
Guido Oelkers |
Management board |
Henrik Stenqvist, Lydia Abad-Franch, Duane H. Barnes, Lena Bjurner, Sofiane Fahmy, Torbjörn Hallberg, Mahmood Ladha, Norbert Oppitz, Daniel Rankin, Armin Reininger, Christine Wesström |
Supervisory board |
Annette Clancy, Christophe Bourdon, Helena Saxon, Staffan Schüberg, Katy Mazibuko, Mats Lek, Anders Ullman, Filippa Stenberg |
Company data
Name: |
Swedish Orphan Biovitrum AB |
Address: |
Tomtebodavägen 23A,Solna 112 76 |
Phone: |
+46-8-697-2000 |
Fax: |
- |
E-mail: |
-
|
Internet: |
www.sobi.com |
Industry: |
Biotechnology |
Sector: |
Biotechnology |
Sub sector: |
Biotechnology |
End of financial year: |
12/31 |
Free Float: |
42.16% |
IPO date: |
- |
Company calendar
CW 29 | 7/16/2024
Interim Report 2nd Quarter/6 Months
|
CW 43 | 10/24/2024
Interim Report 3rd Quarter/9 Months
|